XML 12 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2017
Jun. 30, 2016
Current assets:    
Cash and cash equivalents $ 123.8 $ 68.5
Marketable investment securities 48.3 90.5
Prepaid expenses 9.5 18.4
Inventory 47.4 38.3
Trade accounts receivable, less allowance for doubtful accounts of $8.1 March 31, 2017 and $6.8 June 30, 2016 114.8 91.7
Prepaid taxes 0.1 3.8
Other receivables 4.4 3.3
Total current assets 348.3 314.5
Property, plant and equipment, net 53.0 58.3
Long-term marketable investment securities 53.4 79.9
Intangibles, net 498.1 227.5
Goodwill 315.0 195.3
Other assets   5.0
Total assets 1,267.8 880.5
Current liabilities:    
Accounts payable 26.8 21.1
Accrued liabilities 64.0 49.5
Short-term contingent consideration 128.2  
Deferred revenue 2.7 1.7
Total current liabilities 221.7 72.3
Unrecognized tax benefits 24.9 24.0
Other long-term liabilities 7.2 7.8
Contingent consideration 14.3 10.4
Long-term debt 167.1  
Long-term deferred taxes 84.7 17.9
Total liabilities 519.9 132.4
Commitments and contingencies
Stockholders’ equity:    
Common stock, 68.1 and 69.1 shares outstanding at March 31, 2017 and June 30, 2016 respectively 0.7 0.7
Additional paid-in capital 839.5 830.1
Accumulated other comprehensive loss (10.6) (9.5)
Accumulated deficit (81.4) (73.2)
Total Myriad Genetics, Inc. stockholders’ equity 748.2 748.1
Non-Controlling Interest (0.3)  
Total stockholders' equity 747.9 748.1
Total liabilities and stockholders’ equity $ 1,267.8 $ 880.5